



**CORPORATE HEADQUARTERS
PATENT LAW DEPARTMENT
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NEW JERSEY 08933-7003**

FACSIMILE TRANSMISSION COVER SHEET

DATE: January 7, 2002

TO: Examiner V Balasubramanian

COMPANY: United States Patent & Trademark Office

FACSIMILE NUMBER: (703) ~~746-3154~~ 703 308-4556

FROM: Mary A. Appollina

TELEPHONE NO.: (732) 524-3742

FACSIMILE NUMBER: (732) 524-2808

NUMBER OF PAGES INCLUDING THIS COVER SHEET: 10

**IF THERE IS A PROBLEM WITH THIS TRANSMISSION, PLEASE CALL Mary Appollina
(908) 524-3742**

RE: USSN: 09/430,966 (Attorney Docket: JAB-1425)

COMMENTS:

THIS MESSAGE IS INTENDED ONLY FOR THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE SOLELY TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

Docket No. JAB-1425

#16 E
PS
1/16IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Bart De Corte et al

Serial No. : 09/430,966

Art Unit: 1624

Filed: November 1, 1999

Examiner: V. Balasubramanian

For : HIV REPLICATION INHIBITING PYRIMIDINES

I hereby certify that this correspondence is being facsimile transmitted
to the Patent and Trademark Office, Fax No. (703) 308-4556 on

January 7, 2002

(Date)

Mary A. Appollina

Name of applicant, assignee, or Registered Representative

Mary A. Appollina
(Signature)January 7, 2002

(Date of Signature)

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL AMENDMENT

Dear Sir:

Please amend the above-identified application as follows and
consider the following remarks.

In the Claims:

Add new Claim 21 as follows:

5 21. (New) A method of treating subjects suffering from HIV
(Human Immunodeficiency Virus) infection comprising
administering to the subject a therapeutically effective
amount of a compound of formula